PHARMACY

Lupin launches hydrocodone bitartrate generic

BY Brian Berk

BALTIMORE — Lupin launched hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg in the United States.

Lupin’s hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg are the AA rated generic equivalent of Mikart’s hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg. It is indicated for the relief of moderate to moderately severe pain.

Hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg had combined sales of $79.6 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mayne Pharma acquires rights to fentanyl TDS

BY Brian Berk

ADELAIDE, South Australia — Mayne Pharma acquired the rights to the fentanyl transdermal delivery system, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr from Par Pharmaceutical, which allows the company to now market the product in the United States.

This product was developed by Corium, a specialty pharmaceutical company focused on the development and manufacture of transdermal and transmucosal delivery systems. Fentanyl TDS is a generic equivalent to Duragesic, indicated for the management of pain in opioid-tolerant patients, severe enough to require daily treatment.

Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium. “We are very pleased to have partnered with Corium on another complex, difficult-to-develop and manufacture product,” said Mayne Pharma’s CEO Scott Richards. “The U.S. transdermal patch market is valued at more than $3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance.”  

According to IMS Health, the annual market sales for the fentanyl patch were approximately $560 million for the 12 months ending Dec. 31.

“Mayne Pharma’s first marketed patch was Clonidine, indicated for the treatment of hypertension and is one of Mayne Pharma’s top five generic products by sales,” said Richards. “Our alliance with Corium now includes two marketed and one pipeline product that is filed with the U.S. Food and Drug Administration and reinforces one of the key strategic benefits of the Teva Portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharmaceutical ingredient suppliers and contract development and manufacturing companies.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

SoFi takes a look at best-value pharmacy schools

BY David Salazar
SAN FRANCISCO — Lender and student loan refinancing company SoFi this week conducted a rundown of which pharmacy schools provide students the best bang for their buck by comparing which schools have the highest average salaries relative to their student debt, on average. It also looked at the pharmacy schools’ graduates have the highest average salaries and schools whose graduates have the highest amount of debt relative to their income. 
 
The pharmacy school with the highest average salary was the University of California, San Francisco, which had an average salary of $145,297, which was 1.3 times the average $109,394 in debt students depart with. The University of the Pacific’s pharmacy school came in second, with an average salary of $137,639 and salary-debt ratio of 0.8. It was followed by Midwestern University – Glendale, whose graduates earn $133,867 on average; University of Southern California, with its average graduate salary of $133,328; and Harding University, with its average salary of $132,748. However, all four schools that followed the top slot had students with debt higher than their average salary, and three were below the average of all pharmacy schools. 
 
At the head of the pack of schools with the best salary-debt ratios was North Dakota State University’s Main Campus in Fargo, whose graduates make, on average, 1.7 times what they have in student debt. At the University of Montana, pharmacy grads make 1.6 times their debt, and an average student at Southwestern Oklahoma State university make 1.4 times their debt. The same is true of the University of Kansas’ and Florida Agricultural & Mechanical University’s pharmacy graduates. 
 
“Ample employment opportunities, plus a lower cost of living, can certainly help when it comes to paying down student loans. NDSU might have earned the top ranking on our list because of the healthcare jobs that abound in the area: 81% of 53 counties in North Dakota are short on health professionals,” SoFi’s Barbara Bellesi wrote. “The numbers from University of Montana could tell a similar story: The need for healthcare workers in the state is growing, so the workforce must increase by 40% over the next decade to meet demand. Southwestern Oklahoma State ranks high likely because Oklahoma has seen a 26.56% increase in pharmacist jobs over the past decade
 
SoFi also ranked that it said are the least lucrative, whose students make less annually than they have accrued in debt. SoFi said that the two schools at the bottom of the list —Philadelphia College of Osteopathic Medicine and Regis University — on average produce graduates with twice as much debt as their annual salaries. 
 
“Pharmacy school is a big investment of both time and money, so to have a better shot at paying off student debt faster, it makes sense to apply to schools where employment opportunities abound and earning potential is high,” Bellesi writes. “Pharm.D. graduates are poised to be successful, so choose a school that will prepare you well for a career that fulfills your personal and financial goals.”
 
To see the full rankings, click here
keyboard_arrow_downCOMMENTS

Leave a Reply

S.Mullins says:
Mar-12-2017 12:42 pm

The San Francisco high salary is all well and good, but don't forget to factor in the fact that this is THE MOST EXPENSIVE city in which to live. You cannot compare $ to $ from city to city. Apples and oranges my friend.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?